Michelle Le Beau

Michelle M. Le Beau, Ph.D. is the Arthur and Marian Edelstein Professor Emerita of Medicine, Section of Hematology/Oncology, Director Emerita of the University of Chicago Medicine Comprehensive Cancer Center, an NCI-designated Comprehensive Cancer Center, and Director Emerita of the Cancer Cytogenetics Laboratory at the University of Chicago. She is board-certified in clinical cytogenetics by the ABMGG. 

Dr. Le Beau is a past-President of the Board of Directors of the Association of American Cancer Institutes, and a past member of the Board of Directors for American Association for Cancer Research (AACR) and the Leukemia and Lymphoma Society, as well as the Executive Committee of the American Society of Hematology (ASH), and the National Cancer Policy Forum of the NAM. She currently serves on the Board of Scientific Advisors for the National Cancer Institute, and the Board of Directors for the American Cancer Society. Dr. Le Beau has received a number of honors, including the 22 Margaret Foti Award for Leadership and Extraordinary Accomplishments in Cancer Research from the AACR, and the 22 Henry M. Stratton Award in Basic Sciences from the ASH. 

She was a member of the NIH Pathology B Study Section (1996-21), and CAMP Study Section (21-26, Chair 24-26), as well as a member of the NCI Initial Review Group A, Cancer Centers Review Parent Committee (25-29). She has served on numerous editorial boards, including Blood and British Journal of Hematology, and served as Associate Editor of Genes, Chromosomes, and Cancer (1989-25). Dr. Le Beau has published more than 43 papers and is an international leader in cancer cytogenetics and genetics.  

Dr. Le Beau is recognized for her work in identifying recurring cytogenetic abnormalities, in defining the clinical, morphological, and cytogenetic subsets of leukemia, and in identifying the genetic pathways that lead to myeloid leukemias. Much of her work has focused on therapy-related myeloid neoplasms. She was appointed as the cancer genetics expert for the 28 revision and 214 on-line update of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.

Disclosures: Michelle has no MCED-related relationships to disclose.